MSH 1001

Drug Profile

MSH 1001

Alternative Names: Cardioprotective therapy (KR-31378) - Dongbu Hannong; DNB 001; Glaucoma therapy (DNB-001) - Danube Pharmaceuticals; KR-31378; MSH-1001

Latest Information Update: 08 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Korea Research Institute of Chemical Technology
  • Developer Charlesson; Danube Pharmaceuticals; Korea Research Institute of Chemical Technology
  • Class Anti-ischaemics; Antiglaucomas; Neuroprotectants; Small molecules
  • Mechanism of Action KATP channel stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Glaucoma; Ocular hypertension
  • Discontinued Ischaemia; Ischaemic heart disorders

Most Recent Events

  • 08 Oct 2014 No development reported - Preclinical for Glaucoma in USA (Intraocular)
  • 08 Oct 2014 No development reported - Preclinical for Ocular hypertension in USA (Intraocular)
  • 31 Dec 2011 Discontinued - Phase-I for Glaucoma in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top